S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
Log in

NASDAQ:AKRX - Akorn Stock Price, Forecast & News

$3.74
+0.01 (+0.27 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$3.68
Now: $3.74
$3.76
50-Day Range
$3.64
MA: $4.25
$5.22
52-Week Range
$2.34
Now: $3.74
$5.46
Volume810,930 shs
Average Volume2.10 million shs
Market Capitalization$471.79 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:AKRX
CUSIP00972810
CIK3116
Phone847-279-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$694.02 million
Cash Flow$0.34 per share
Book Value$3.54 per share

Profitability

Net Income$-401,910,000.00

Miscellaneous

Employees2,191
Market Cap$471.79 million
Next Earnings DateN/A
OptionableOptionable

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter.


Akorn (NASDAQ:AKRX) Frequently Asked Questions

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) issued its earnings results on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.06. The company earned $176.24 million during the quarter, compared to the consensus estimate of $176.15 million. Akorn had a negative return on equity of 19.95% and a negative net margin of 53.62%. Akorn's quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.06) earnings per share. View Akorn's Earnings History.

What price target have analysts set for AKRX?

3 brokers have issued 1 year price objectives for Akorn's shares. Their forecasts range from $4.00 to $8.00. On average, they expect Akorn's stock price to reach $5.67 in the next year. This suggests a possible upside of 51.5% from the stock's current price. View Analyst Price Targets for Akorn.

What is the consensus analysts' recommendation for Akorn?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn.

Has Akorn been receiving favorable news coverage?

News coverage about AKRX stock has been trending neutral on Tuesday, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Akorn earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Akorn.

Are investors shorting Akorn?

Akorn saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 7,650,000 shares, a drop of 17.6% from the September 30th total of 9,280,000 shares. Based on an average daily volume of 1,860,000 shares, the short-interest ratio is currently 4.1 days. Approximately 8.1% of the company's stock are short sold. View Akorn's Current Options Chain.

Who are some of Akorn's key competitors?

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Who are Akorn's key executives?

Akorn's management team includes the folowing people:
  • Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
  • Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
  • Dr. Bruce Kutinsky, Consultant (Age 53)
  • Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)

Who are Akorn's major shareholders?

Akorn's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.66%), State Street Corp (2.60%), Canyon Capital Advisors LLC (2.38%), Mackay Shields LLC (0.57%), Gabelli Funds LLC (0.35%) and Gamco Investors INC. ET AL (0.29%). Company insiders that own Akorn stock include Alan D Weinstein, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

Which major investors are selling Akorn stock?

AKRX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, State Street Corp, Assenagon Asset Management S.A., Barclays PLC, SG Americas Securities LLC, Chicago Equity Partners LLC and Gabelli Funds LLC. View Insider Buying and Selling for Akorn.

Which major investors are buying Akorn stock?

AKRX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Mackay Shields LLC, Canyon Capital Advisors LLC, Tibra Equities Europe Ltd, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Gamco Investors INC. ET AL and California Public Employees Retirement System. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

How do I buy shares of Akorn?

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akorn's stock price today?

One share of AKRX stock can currently be purchased for approximately $3.74.

How big of a company is Akorn?

Akorn has a market capitalization of $471.79 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

What is Akorn's official website?

The official website for Akorn is http://www.akorn.com/.

How can I contact Akorn?

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]


MarketBeat Community Rating for Akorn (NASDAQ AKRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  530 (Vote Outperform)
Underperform Votes:  455 (Vote Underperform)
Total Votes:  985
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: Percentage Gainers

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel